Contrasting Apogee Therapeutics (NASDAQ:APGE) & CytomX Therapeutics (NASDAQ:CTMX)

Apogee Therapeutics (NASDAQ:APGE) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Insider & Institutional Ownership

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 42.8% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Apogee Therapeutics and CytomX Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-34.65%	-32.76%
CytomX Therapeutics	34.04%	158.70%	36.04%

Earnings and Valuation

This table compares Apogee Therapeutics and CytomX Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$182.15 million	($4.13)	-13.70
CytomX Therapeutics	$141.10 million	4.17	$31.87 million	$0.56	6.38

CytomX Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Apogee Therapeutics has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Apogee Therapeutics and CytomX Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1	1	8	1	2.82
CytomX Therapeutics	0	1	6	0	2.86

Apogee Therapeutics currently has a consensus target price of $94.00, suggesting a potential upside of 66.11%. CytomX Therapeutics has a consensus target price of $5.83, suggesting a potential upside of 63.40%. Given Apogee Therapeutics’ higher possible upside, equities research analysts clearly believe Apogee Therapeutics is more favorable than CytomX Therapeutics.

Summary

CytomX Therapeutics beats Apogee Therapeutics on 9 of the 14 factors compared between the two stocks.

About Apogee Therapeutics

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

About CytomX Therapeutics

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.